Loading stock data…
BRTX
$0.23+0.01 (+3.60%)
Market ClosedLast close May 1
BioRestorative Therapies, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioRestorative Therapies, Inc. in the Healthcare sector is trading at $0.23. The stock is currently near its 52-week low of $0.19, remaining 78.0% below its 200-day moving average. Technical signals show neutral RSI of 38 and bullish MACD crossover, explaining why BRTX maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.23
Potential Upside
5%
Whystock Fair Value$0.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-4467.58%
Volume
Today's trading volume
795,146
Recent News
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing
Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +13.51% and -90.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates
ABSCI CORP (ABSI) delivered earnings and revenue surprises of -40.24% and -82.15%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -58.33% and +4.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -17.02% and -72.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?